NEWS

The addition of abemaciclib (Verzenio) to initial treatment with a nonsteroidal aromatase inhibitor appeared effective for women with hormone receptor-positive, HER-2-negative advanced breast cancer, according to results of the double-blind, phase 3 MONARCH 3 study presented at American Association for Cancer Research Annual Meeting. Read More Here 

Basilea Pharmaceutica Ltd. (SIX: BSLN) announced on 4/17/18 that it has entered into a license agreement with ArQule, Inc. (NASDAQ: ARQL) for its oral oncology drug candidate ARQ 087 (derazantinib), which targets the fibroblast growth factor receptor (FGFR) family of kinases. Read More Here

Members of Texas Oncology1, an independent, physician-led practice, were recently introduced to Oral Cancer Treatment (OCE). OCE was conceived by the National Community Oncology Dispensing Association, Inc. (NCODA)2 as a resource to provide information about oral chemotherapy drugs and their side effects to both cancer patients and caregivers. OCE sheets are written with the needs […]

The NCODA Living the Mission Award was established to recognize those member practitioners who exemplify the mission and values of NCODA in its quest to advance the value of dispensing practices for community oncology physicians and deliver positive outcomes through collaboration with all stakeholders involved in the care of oncology patients.

Excellence in Contributing to Care Management Strategies NCODA member practice Texas Oncology was awarded a PBMI 2018 Excellence Award, demonstrating excellence in contributing to Care Management Strategies for quality improvement with the Medically Integrated Pharmacy Care Model. NCODA Chair Jim Schwartz, RPh, Executive Director, Pharmacy Operations of Texas Oncology, received the award and said “We have been […]

Oncology nurse navigators provide the “constant” in what seem to be undulating waves of changes to workflows, the adoption of new technology, the near-weekly onslaught of new drugs, and the need to ensure every nuance of documentation is entered in discrete fields in electronic health records so the practice meets reporting requirements. Read more here.

Accumulator programs target specialty drugs for which a manufacturer provides copayment assistance. Unlike conventional benefit designs, the manufacturer’s payments no longer count toward a patient’s deductible or out-of-pocket maximum. Plan sponsors (employers and health plans) will save big money because accumulators shift a majority of drug costs to patients and manufacturers. Accumulator programs will further lower […]

The Pharmaceutical Research and Manufacturers of America (PhRMA) recently unveiled new advertisements as part of its “Let’s Talk About Cost” campaign highlighting how the use of copay accumulator programs by insurance companies and other middlemen could result in patients facing thousands of dollars in unexpected medical costs. These programs block the copay coupons biopharmaceutical companies […]

Mission Statement Dr. Chirantan Ghosh founded The Ghosh Center with the philosophy of putting the interests of patients first and providing the highest quality of care with compassion and professionalism. Our core philosophy is that patients come first. We stand by the principles: Beneficence: doing good for our patients Nonmaleficence: do no harm Justice: treating patients with […]

Mission Statement Cancer Partners of Nebraska provides comprehensive cancer care in Lincoln and the surrounding areas, combining advanced medical oncology, radiation oncology and pharmacy services.

Outdated Cost-Sharing Policies Limit Patients’ Access to New Lifesaving Drugs Insurers do not offer comparable cost-sharing for many newer medicines administered by patients, including pills taken orally. Instead, most of those treatments are covered by a plan’s prescription benefit, which often require patients to pay much more out-of-pocket.